Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2025 Aug 21;55(4):207-214.
doi: 10.4274/tjo.galenos.2025.67513.

Adalimumab in Focus: Evaluating Effectiveness and Safety in Non-Infectious Uveitis at a Tertiary Referral Center in Türkiye

Berru Yargı Özkoçak  1 , Çiğdem Altan  1 , Burcu Kemer Atik  1 , Berna Başarır  2
Affiliations
Observational Study

Adalimumab in Focus: Evaluating Effectiveness and Safety in Non-Infectious Uveitis at a Tertiary Referral Center in Türkiye

Berru Yargı Özkoçak et al. Turk J Ophthalmol. .

Abstract
in English, Turkish

Objectives: To evaluate the indications, efficacy, and safety of adalimumab (ADA) in treating active non-infectious uveitis (NIU) in the Turkish population in a real-world setting.

Materials and methods: This retrospective observational study included patients diagnosed with NIU treated with ADA on-label. The study assessed the impact of ADA treatment on best corrected visual acuity (BCVA), number of immunosuppressive therapies (IST), immunosuppressive drug load, and the frequency of required local treatment. BCVA was monitored at baseline and subsequent months to determine the onset of functional efficiency of ADA treatment.

Results: A total of 289 eyes of 146 patients (60 females, 86 males) diagnosed with NIU and treated according to the ADA protocol were included in the study. The mean age was 37.6±14.4 years (range, 4-73) and the median follow-up was 30 months (interquartile range, 18-57). The most common indication for ADA was panuveitis, with a diagnosis of Behçet's uveitis. The use of ADA reduced the number of IST, immunosuppressive drug load, and need for local treatment (p<0.001, 0.002, and <0.001, respectively). Corticosteroids could be discontinued in all but one patient. Following ADA, a significant improvement in BCVA was observed from the first month (p<0.001 for baseline vs. month 1) and stabilization occurred after the sixth month (p=0.751 for month 6 vs. 12). Side effects were reported by 55.2% of patients during IST, while only 8 patients (5.5%) experienced ADA-related side effects. At the end of the follow-up period, 8.9% of patients switched to a weekly dosing schedule. Patients who switched to a weekly regimen required more local treatment before and after ADA treatment (p=0.02 and 0.001, respectively), and the number of concomitant IST and drug load were higher during standard-dose ADA use (p<0.001 and p=0.025, respectively).

Conclusion: This study, the largest single-center investigation in Türkiye, reveals ADA to be a safe option with functional benefits across diverse indications and age ranges. Notably, ADA minimizes reliance on additional therapies.

Amaç: Türk popülasyonunda aktif non-enfeksiyöz üveit (NEÜ) tedavisinde adalimumabın (ADA) endikasyonlarını, etkinliğini ve güvenliliğini değerlendirmek.

Gereç ve yöntem: Bu retrospektif gözlemsel çalışmaya ADA ile tedavi edilen NEÜ tanılı hastalar dahil edilmiştir. Çalışmada ADA tedavisinin en iyi düzeltilmiş görme keskinliği (EİDGK), immünosüpresif tedavi (İST) sayısı, immünosüpresif ilaç yükü ve gereken lokal tedavi sıklığı üzerindeki etkisi değerlendirilmiştir. ADA tedavisinin fonksiyonel etkinliğinin başlangıcını belirlemek için başlangıçta ve sonraki aylarda EİDGK değişimi izlenmiştir.

Bulgular: NEÜ tanısı konan ve ADA protokolüne göre tedavi edilen 146 hastanın (60 kadın, 86 erkek) toplam 289 gözü çalışmaya dahil edildi. Ortalama yaş 37,6±14,4 (aralık 4-73) yıl ve medyan takip süresi 30 (çeyrekler arası aralık 18-57) aydı. ADA için en yaygın endikasyon Behçet üveiti tanısı ile panüveitti. ADA kullanımı İST sayısını, immünosüpresif ilaç yükünü ve lokal tedavi ihtiyacını azalttı (p<0,001, 0,002 ve <0,001, sırasıyla). Bir hasta hariç tüm hastalarda KS’ler kesilebildi. ADA kullanımını takiben, birinci aydan itibaren EİDGK’da belirgin bir iyileşme gözlendi (p<0,001) ve altıncı aydan sonra stabilizasyon oluştu (p=0,751; 6-12 ay değişim). Hastaların %55,2’si İST sırasında yan etki yaşarken, sadece 8 hasta (%5,5) ADA ile ilişkili yan etki yaşadı. Takip süresinin sonunda, hastaların %8,9’u haftalık doz rejimine geçti. Haftalık rejime geçen hastalar ADA tedavisinden önce ve sonra daha fazla lokal tedaviye ihtiyaç duydu (p=0,02 ve 0,001, sırasıyla) ve standart doz ADA kullanımı sırasında eşlik eden İST sayısı ve ilaç yükü daha yüksekti (p<0,001 ve p=0,025, sırasıyla).

Sonuç: Türkiye’deki en büyük tek merkezli araştırma olan bu çalışma, ADA’nın farklı endikasyonlar ve yaş aralıklarında işlevsel faydalar sağlayan güvenli bir seçenek olduğunu ortaya koymaktadır. Özellikle, ADA ek tedavilere olan bağımlılığı azaltmaktadır.

Keywords: Adalimumab; Behçet uveitis; TNF-α antagonist; immunosuppressive drug load; non-infectious uveitis.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: No conflict of interest was declared by the authors.

Figures

Figure 1
Figure 1
Adalimumab (ADA) use status of patients *Remission was diagnosed in three patients with Behçet’s uveitis, one with sarcoidosis and one with Vogt-Koyanagi-Harada (VKH) disease **ADA treatment was discontinued in 2 patients with serpiginous choroiditis due to skin rash, 1 patient with serpiginous choroiditis due to pulmonary tuberculosis and 1 patient with VKH due to lymph adenopathy. The symptoms of dermatological conditions that manifested during ADA administration abated with the cessation of ADA and did not recur upon the resumption of ADA
Figure 2
Figure 2
Changes in the mean best corrected visual acuity (BCVA). Patients diagnosed with spondyloarthropathy-associated uveitis were excluded (Wilcoxon signed-rank test) logMAR: Logarithm of the minimum angle of resolution
See this image and copyright information in PMC

References

    1. Tsirouki T, Dastiridou A, Symeonidis C, Tounakaki O, Brazitikou I, Kalogeropoulos C, Androudi S. A focus on the epidemiology of uveitis. Ocul Immunol Inflamm. 2018;26(1):2–16. doi: 10.1080/09273948.2016.1196713. - DOI - PubMed
    1. Yalçındağ FN, Özdal PC, Özyazgan Y, Batıoğlu F, Tugal-Tutkun I, BUST Study Group. 1. Vol. 26. BUST Study Group. Demographic and clinical characteristics of uveitis in Turkey: the first national registry report; 2018. Ocul Immunol Inflamm. pp. 17–26. - DOI - PubMed
    1. Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Huseyin Altunbas H, Urgancioglu M. Uveitis in Behçet disease: an analysis of 880 patients. Am J Ophthalmol. 2004;138(3):373–380. doi: 10.1016/j.ajo.2004.03.022. - DOI - PubMed
    1. Zierhut M, Abu El-Asrar AM, Bodaghi B, Tugal-Tutkun I. Therapy of ocular Behçet disease. Ocul Immunol Inflamm. 2014;22(1):64–76. doi: 10.3109/09273948.2013.866257. - DOI - PubMed
    1. Akkoç N. Update on the epidemiology, risk factors and disease outcomes of Behçet’s disease. Best Pract Res Clin Rheumatol. 2018;32(2):261–270. doi: 10.1016/j.berh.2018.08.010. - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources